Interleukin-6 in Rheumatoid Arthritis
<b>: </b>The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumato...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/15/5238 |
id |
doaj-f7c3d57f3aaf43c1b33cc285e8bf03d6 |
---|---|
record_format |
Article |
spelling |
doaj-f7c3d57f3aaf43c1b33cc285e8bf03d62020-11-25T03:26:33ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-07-01215238523810.3390/ijms21155238Interleukin-6 in Rheumatoid ArthritisFranco Pandolfi0Laura Franza1Valentina Carusi2Simona Altamura3Gloria Andriollo4Eleonora Nucera5Allergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyEmergency Medicine, Fondazione Policlinico Universitario A, Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, Italy<b>: </b>The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.https://www.mdpi.com/1422-0067/21/15/5238IL-6rheumatoid arthritisinflammation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Franco Pandolfi Laura Franza Valentina Carusi Simona Altamura Gloria Andriollo Eleonora Nucera |
spellingShingle |
Franco Pandolfi Laura Franza Valentina Carusi Simona Altamura Gloria Andriollo Eleonora Nucera Interleukin-6 in Rheumatoid Arthritis International Journal of Molecular Sciences IL-6 rheumatoid arthritis inflammation |
author_facet |
Franco Pandolfi Laura Franza Valentina Carusi Simona Altamura Gloria Andriollo Eleonora Nucera |
author_sort |
Franco Pandolfi |
title |
Interleukin-6 in Rheumatoid Arthritis |
title_short |
Interleukin-6 in Rheumatoid Arthritis |
title_full |
Interleukin-6 in Rheumatoid Arthritis |
title_fullStr |
Interleukin-6 in Rheumatoid Arthritis |
title_full_unstemmed |
Interleukin-6 in Rheumatoid Arthritis |
title_sort |
interleukin-6 in rheumatoid arthritis |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-07-01 |
description |
<b>: </b>The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far. |
topic |
IL-6 rheumatoid arthritis inflammation |
url |
https://www.mdpi.com/1422-0067/21/15/5238 |
work_keys_str_mv |
AT francopandolfi interleukin6inrheumatoidarthritis AT laurafranza interleukin6inrheumatoidarthritis AT valentinacarusi interleukin6inrheumatoidarthritis AT simonaaltamura interleukin6inrheumatoidarthritis AT gloriaandriollo interleukin6inrheumatoidarthritis AT eleonoranucera interleukin6inrheumatoidarthritis |
_version_ |
1724592054043934720 |